HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestle Health Grows: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

Nestle to pay $2.3bn for firm Atrium Innovations, owner of US plant-based supplement marketer Garden of Life and other nutritional brands; Wellness Resources warned on disease claims for omega-3s; and latest health and wellness sector recalls.

You may also be interested in...



Garden Of Life Survey Points To Consumer Preference For Carbon-Neutral Product Providers

More than 4 in 5 American adults expect companies to be carbon neutral consider a company’s climate impact and sustainability record when selecting a product, research conducted by certified carbon neutral dietary supplement brand Garden of Life reports.

Hofseth Biocare’s ProGo Salmon Protein Spawns In US With Garden Of Life

Deal stemming from a 2019 letter of intent by Garden of Life calls for it to co-brand products with ProGo logo on packaging to ensure consumer traceability and full transparency of the supply chain.

Nestle Personalized Nutrition Expands In Americas, Health Science Business Revenues Grow In Q1

Nestle expands its personalized nutrition offerings in the Americas with nesQino, featuring a digital app to make hot or cold beverages. It also reported consumer stockpiling boost its first-quarter Health Science sales. It continues to seek acquisitions, despite COVID-19 epidemic's drag on economic markets.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel